Chief Executive Officer
Dr Rojkjaer is a board-certified haematologist with more than 15 years of expertise from global and regional clinical development and medical affairs in the biotech and pharma industries. She has extensive experience in the development of both biologics and small molecules in haematology and immunology. Previous positions include global clinical program head, oncology global development at Novartis Pharmaceuticals, chief medical officer at Molecular Partners, and vice president, head of clinical development at Morphosys AG and director of clinical development, hematology in the US for Novo Nordisk. Dr Rojkjaer holds a medical degree from the University of Toronto and is board-certified in both internal medicine and haematology. She joined Nordic Nanovector in November 2016.